Scarica l'app Stockscreener
212.26
2.02%
4.20
Pre-mercato:
224.00
11.74
+5.53%
Precedente Chiudi:
$208.06
Aprire:
$209.71
Volume 24 ore:
1.21M
Relative Volume:
1.29
Capitalizzazione di mercato:
$13.32B
Reddito:
$4.27B
Utile/perdita netta:
$-356.15M
Rapporto P/E:
-35.55
EPS:
-5.9702
Flusso di cassa netto:
$1.19B
1 W Prestazione:
+4.06%
1M Prestazione:
+13.54%
6M Prestazione:
+54.69%
1 anno Prestazione:
+79.59%
Intervallo 1D:
$208.41
$212.57
Intervallo di 1 settimana:
$198.68
$212.57
Portata 52W:
$97.50
$212.57
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
212.26 | 13.05B | 4.27B | -356.15M | 1.19B | -5.9702 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Ripresa | Raymond James | Outperform |
| 2026-02-27 | Iniziato | Barclays | Overweight |
| 2025-11-24 | Downgrade | UBS | Buy → Neutral |
| 2025-07-15 | Iniziato | Deutsche Bank | Buy |
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Jazz Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
Jazz (JAZZ) Q1 2026 Earnings Call Transcript - The Globe and Mail
MSN Money - MSN
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates - Yahoo Finance Singapore
Earnings call transcript: Jazz Pharmaceuticals Q1 2026 earnings beat expectations By Investing.com - Investing.com Canada
Jazz Pharmaceuticals plc 2026 Q1ResultsEarnings Call Presentation (NASDAQ:JAZZ) 2026-05-05 - Seeking Alpha
Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - Benzinga
Jazz Pharmaceuticals surges on earnings beat, strong revenue By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals surges on earnings beat, strong revenue - Investing.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surges 3.7% After-Hours on Q1 2026 Revenue and EPS Beat - ChartMill
Jazz: Q1 Earnings Snapshot - wwltv.com
(JAZZ) Jazz Pharmaceuticals Expects Full Year 2026 Revenue Range $4.25B$4.50B, vs. FactSet Est of $4.44B - marketscreener.com
Bruce Cozadd sells 6,000 Jazz (NASDAQ: JAZZ) shares under 10b5-1 plan - Stock Titan
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Reports Q1 Revenue $1.07B, vs. FactSet Est of $978.5M - marketscreener.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q1 CY2026 Sales - Yahoo Finance
Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q1 Adjusted EPS $6.34 per Share - marketscreener.com
Jazz Pharmaceuticals (NASDAQ: JAZZ) swings to Q1 2026 profit on PRV sale - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) posts 19% Q1 revenue growth - Stock Titan
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results - Bolsamania
All eyes on Jazz Pharmaceuticals earnings as FDA decision nears By Investing.com - Investing.com Canada
All eyes on Jazz Pharmaceuticals earnings as FDA decision nears - Investing.com
Jazz Pharmaceuticals stock hits all-time high at 207.49 USD By Investing.com - Investing.com India
Jazz Pharmaceuticals stock hits all-time high at 207.49 USD - Investing.com
Jazz Pharmaceuticals (JAZZ) Q1 Earnings Report Preview: What To Look For - Yahoo Finance
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Jazz Pharmaceuticals PLC (JAZZ) - MSN
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Ziihera Priority Review Milestone - simplywall.st
Jazz Pharmaceuticals (NASDAQ: JAZZ) reports two 6,000-share Rule 144 sales - Stock Titan
JAZZ Forecast, Price Target & Analyst Ratings | JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) - ChartMill
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Sees Significant Decline in Short Interest - MarketBeat
Vanguard Capital Management reports 5.04% stake in Jazz Pharmaceuticals (NASDAQ: JAZZ) - Stock Titan
Will Ziihera’s Priority Review in First-Line HER2-Positive Gastric Cancer Shift Jazz Pharmaceuticals’ (JAZZ) Narrative? - simplywall.st
Pictet Asset Management Holding SA Sells 33,547 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
M&T Bank Corp Purchases New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
US Cannabis Market Report Analysis Report 2026-2034 Featuring Canopy Growth, Tilray Brands, Curaleaf, Aurora Cannabis, Jazz Pharma, GTI, Trulieve, Cresco Labs, Organigram Global, TerrAscend - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Market Driver Insights: The Impact of Recent Developments on the Erwinaze/Spectrila Market - openPR.com
FDA accepts Jazz Pharma filing for Ziihera in gastric cancer By Investing.com - Investing.com South Africa
FDA accepts Jazz Pharma filing for Ziihera in gastric cancer - Investing.com UK
Wells Fargo Maintains Jazz Pharmaceuticals (JAZZ) Overweight Recommendation - MSN
How ASCO Phase 3 Oncology Data May Reshape Jazz Pharmaceuticals' (JAZZ) Investment Narrative - Yahoo Finance
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks - Yahoo Finance
Jazz Pharmaceuticals announces FDA acceptance and Priority Review of supplemental biologics license application for Ziihera - marketscreener.com
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA - PR Newswire
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A Biotech Powerhouse with a 14.76% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals enters exclusive licensing deal with Saniona - msn.com
Universal Beteiligungs und Servicegesellschaft mbH Has $15.32 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Polaris Capital Management LLC Sells 81,000 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Executive Compensation Program 2025: Structure, Philosophy, and Key Features Explained - Minichart
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference - 富途牛牛
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):